News Focus
News Focus
Replies to #89383 on Biotech Values
icon url

DewDiligence

01/21/10 6:42 PM

#89384 RE: mcbio #89383

No surprise there. This is a case where the tape was a pretty good tip-off that a financing was in the works. I’d be willing to bet that this deal has been widely known for the past couple of weeks.

Inasmuch as ACHN is one of my SI charity holdings, I hope the deal terms are OK :- )
icon url

turtlepower

01/21/10 7:11 PM

#89391 RE: mcbio #89383

ACHN - It would have made more sense to offer shares when the price was in the mid 3's. Seems to me they were holding off until Clarus could sell of as many shares as possible. Pretty sneaky IMO and I'm normally leery of such management.
icon url

drbio45

01/21/10 7:19 PM

#89393 RE: mcbio #89383

achn

you actually worry too much about dilution.

If they raise a lot of money the stock will be able to go up because they will have enough money to progress the drugs further. If the drugs show good results the Hep C market is big enough to maintain a high market cap.

The writing was on the wall that this financing was going to get done. I do mot know why the didn't do a quick deal when the stock was in the three's

Dew, I see that you are saying that they attempted to get the deal done in the three's. I am not so sure about that
icon url

turtlepower

01/22/10 7:37 AM

#89414 RE: mcbio #89383

ACHN - Offering priced at 2.08 with almost 50% of current number of shares being offered

NEW HAVEN, Conn., Jan. 22, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN - News), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that it has priced a firm commitment underwritten public offering of 10,275,000 shares of its common stock at public offering price of $2.08 per share. The Company has also granted to the underwriters an option to acquire up to an additional 1,541,250 shares to cover overallotments in connection with the offering. The Company expects that the net proceeds of the offering will be approximately $19.7 million, assuming no exercise of the overallotment option. The net proceeds of the offering will be used for general corporate purposes. The offering is expected to close on January 27, 2010.

http://finance.yahoo.com/news/Achillion-Prices-214-Million-pz-1964553912.html?x=0&.v=1